{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:58:49Z","timestamp":1777564729318,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1007\/s12325-016-0455-x","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T05:55:54Z","timestamp":1480658154000},"page":"78-90","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Sirukumab: A Potential Treatment for Mood Disorders?"],"prefix":"10.1007","volume":"34","author":[{"given":"Aileen J.","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yena","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Salvadore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trehani M.","family":"Fonseka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sidney H.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger S.","family":"McIntyre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,12,2]]},"reference":[{"issue":"3","key":"455_CR1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s12325-014-0105-0","volume":"31","author":"RS McIntyre","year":"2014","unstructured":"McIntyre RS. A vision for drug discovery and development: novel targets and multilateral partnerships. Adv Ther. 2014;31(3):245\u20136.","journal-title":"Adv Ther"},{"issue":"11","key":"455_CR2","doi-asserted-by":"crossref","first-page":"869","DOI":"10.4088\/JCP.v62n1106","volume":"62","author":"AR Entsuah","year":"2001","unstructured":"Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry. 2001;62(11):869\u201377.","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"455_CR3","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1176\/appi.ajp.159.8.1354","volume":"159","author":"N Casacalenda","year":"2002","unstructured":"Casacalenda N, Perry JC, Looper K. Remission in major depressive disorder: a comparison of pharmacotherapy, psychotherapy, and control conditions. Am J Psychiatry. 2002;159(8):1354\u201360.","journal-title":"Am J Psychiatry"},{"issue":"3","key":"455_CR4","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1600-0447.2009.01519.x","volume":"122","author":"F Hardeveld","year":"2010","unstructured":"Hardeveld F, Spijker J, De Graaf R, Nolen WA, Beekman AT. Prevalence and predictors of recurrence of major depressive disorder in the adult population. Acta Psychiatr Scand. 2010;122(3):184\u201391.","journal-title":"Acta Psychiatr Scand"},{"issue":"15","key":"455_CR5","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1007\/s00213-014-3467-8","volume":"231","author":"AA Crawford","year":"2014","unstructured":"Crawford AA, Lewis S, Nutt D, et al. Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals. Psychopharmacology. 2014;231(15):2921\u201331.","journal-title":"Psychopharmacology"},{"issue":"1\u20133","key":"455_CR6","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jad.2009.03.017","volume":"120","author":"P Bob","year":"2010","unstructured":"Bob P, Raboch J, Maes M, et al. Depression, traumatic stress and interleukin-6. J Affect Disord. 2010;120(1\u20133):231\u20134.","journal-title":"J Affect Disord"},{"issue":"2","key":"455_CR7","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.pnpbp.2007.09.015","volume":"32","author":"T Eller","year":"2008","unstructured":"Eller T, Vasar V, Shlik J, Maron E. Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2):445\u201350.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"3","key":"455_CR8","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.biopsych.2009.01.030","volume":"66","author":"D Lindqvist","year":"2009","unstructured":"Lindqvist D, Janelidze S, Hagell P, et al. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry. 2009;66(3):287\u201392.","journal-title":"Biol Psychiatry"},{"issue":"1\u20132","key":"455_CR9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0165-0327(95)00049-6","volume":"36","author":"M Maes","year":"1995","unstructured":"Maes M, Vandoolaeghe E, Ranjan R, Bosmans E, Bergmans R, Desnyder R. Increased serum interleukin-1-receptor-antagonist concentrations in major depression. J Affect Disord. 1995;36(1\u20132):29\u201336.","journal-title":"J Affect Disord"},{"issue":"6","key":"455_CR10","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/scan\/nst041","volume":"9","author":"F Zeidan","year":"2014","unstructured":"Zeidan F, Martucci KT, Kraft RA, McHaffie JG, Coghill RC. Neural correlates of mindfulness meditation-related anxiety relief. Soc Cogn Affect Neurosci. 2014;9(6):751\u20139.","journal-title":"Soc Cogn Affect Neurosci"},{"issue":"3","key":"455_CR11","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1037\/a0035302","volume":"140","author":"GM Slavich","year":"2014","unstructured":"Slavich GM, Irwin MR. From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. Psychol Bull. 2014;140(3):774\u2013815.","journal-title":"Psychol Bull"},{"key":"455_CR12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbi.2013.04.009","volume":"31","author":"CL Raison","year":"2013","unstructured":"Raison CL, Miller AH. Malaise, melancholia and madness: the evolutionary legacy of an inflammatory bias. Brain Behav Immun. 2013;31:1\u20138.","journal-title":"Brain Behav Immun"},{"issue":"5","key":"455_CR13","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.biopsych.2009.09.033","volume":"67","author":"Y Dowlati","year":"2010","unstructured":"Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67(5):446\u201357.","journal-title":"Biol Psychiatry"},{"issue":"10","key":"455_CR14","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1017\/S1461145714000819","volume":"17","author":"V Stelzhammer","year":"2014","unstructured":"Stelzhammer V, Haenisch F, Chan MK, et al. Proteomic changes in serum of first onset, antidepressant drug-na\u00efve major depression patients. Int J Neuropsychopharmacol. 2014;17(10):1599\u2013608.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"455_CR15","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.neuroscience.2009.03.080","volume":"164","author":"JH Barnett","year":"2009","unstructured":"Barnett JH, Smoller JW. The genetics of bipolar disorder. Neuroscience. 2009;164(1):331\u201343.","journal-title":"Neuroscience"},{"issue":"3","key":"455_CR16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.molmed.2007.12.007","volume":"14","author":"WE Naugler","year":"2008","unstructured":"Naugler WE, Karin M. The wolf in sheep\u2019s clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med. 2008;14(3):109\u201319.","journal-title":"Trends Mol Med"},{"issue":"6","key":"455_CR17","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1056\/NEJM199902113400607","volume":"340","author":"C Gabay","year":"1999","unstructured":"Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340(6):448\u201354.","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"455_CR18","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/ar1916","volume":"8","author":"T Kishimoto","year":"2006","unstructured":"Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther. 2006;8(Suppl 2):S2.","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"455_CR19","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI119488","volume":"99","author":"C Gabay","year":"1997","unstructured":"Gabay C, Smith MF, Eidlen D, Arend WP. Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. J Clin Invest. 1997;99(12):2930\u201340.","journal-title":"J Clin Invest"},{"issue":"1","key":"455_CR20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1182\/blood.V83.1.113.113","volume":"83","author":"H Tilg","year":"1994","unstructured":"Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood. 1994;83(1):113\u20138.","journal-title":"Blood"},{"issue":"4","key":"455_CR21","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1517\/13543784.2014.998334","volume":"24","author":"TM Fonseka","year":"2015","unstructured":"Fonseka TM, McIntyre RS, Soczynska JK, Kennedy SH. Novel investigational drugs targeting IL-6 signaling for the treatment of depression. Expert Opin Investig Drugs. 2015;24(4):459\u201375.","journal-title":"Expert Opin Investig Drugs"},{"key":"455_CR22","doi-asserted-by":"publisher","unstructured":"Haroon E, Miller AH. Inflammation effects on brain glutamate in depression: mechanistic considerations and treatment implications. Curr Top Behav Neurosci. 2016. doi: 10.1007\/7854_2016_40","DOI":"10.1007\/7854_2016_40"},{"key":"455_CR23","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jad.2015.08.058","volume":"188","author":"JD Rosenblat","year":"2015","unstructured":"Rosenblat JD, Brietzke E, Mansur RB, Maruschak NA, Lee Y, McIntyre RS. Inflammation as a neurobiological substrate of cognitive impairment in bipolar disorder: evidence, pathophysiology and treatment implications. J Affect Disord. 2015;188:149\u201359.","journal-title":"J Affect Disord"},{"issue":"7","key":"455_CR24","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s40263-015-0263-x","volume":"29","author":"RS McIntyre","year":"2015","unstructured":"McIntyre RS, Xiao HX, Syeda K, et al. The prevalence, measurement, and treatment of the cognitive dimension\/domain in major depressive disorder. CNS Drugs. 2015;29(7):577\u201389.","journal-title":"CNS Drugs"},{"key":"455_CR25","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.comppsych.2014.08.051","volume":"56","author":"RS McIntyre","year":"2015","unstructured":"McIntyre RS, Soczynska JZ, Woldeyohannes HO, et al. The impact of cognitive impairment on perceived workforce performance: results from the International Mood Disorders Collaborative Project. Compr Psychiatry. 2015;56:279\u201382.","journal-title":"Compr Psychiatry"},{"issue":"4","key":"455_CR26","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0893-133X(99)00134-7","volume":"22","author":"S Lanquillon","year":"2000","unstructured":"Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology. 2000;22(4):370\u20139.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"455_CR27","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jpsychires.2012.12.001","volume":"47","author":"D Sasayama","year":"2013","unstructured":"Sasayama D, Hattori K, Wakabayashi C, et al. Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder. J Psychiatr Res. 2013;47(3):401\u20136.","journal-title":"J Psychiatr Res"},{"issue":"2","key":"455_CR28","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.bbi.2010.10.010","volume":"25","author":"S Janelidze","year":"2011","unstructured":"Janelidze S, Mattei D, Westrin \u00c5, Tr\u00e4skman-Bendz L, Brundin L. Cytokine levels in the blood may distinguish suicide attempters from depressed patients. Brain Behav Immun. 2011;25(2):335\u20139.","journal-title":"Brain Behav Immun"},{"issue":"3","key":"455_CR29","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jad.2013.06.004","volume":"150","author":"V Valkanova","year":"2013","unstructured":"Valkanova V, Ebmeier KP, Allan CL. CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies. J Affect Disord. 2013;150(3):736\u201344.","journal-title":"J Affect Disord"},{"issue":"12","key":"455_CR30","doi-asserted-by":"crossref","first-page":"e1428","DOI":"10.4088\/JCP.14m09009","volume":"75","author":"CD Rethorst","year":"2014","unstructured":"Rethorst CD, Bernstein I, Trivedi MH. Inflammation, obesity, and metabolic syndrome in depression: analysis of the 2009-2010 National Health and Nutrition Examination Survey (NHANES). J Clin Psychiatry. 2014;75(12):e1428\u201332.","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"455_CR31","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/mp.2008.48","volume":"14","author":"SJ Bull","year":"2009","unstructured":"Bull SJ, Huezo-Diaz P, Binder EB, et al. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol Psychiatry. 2009;14(12):1095\u2013104.","journal-title":"Mol Psychiatry"},{"issue":"4","key":"455_CR32","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.biopsych.2008.08.010","volume":"65","author":"CL Raison","year":"2009","unstructured":"Raison CL, Borisov AS, Majer M, et al. Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol Psychiatry. 2009;65(4):296\u2013303.","journal-title":"Biol Psychiatry"},{"issue":"2","key":"455_CR33","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1365-2125.2011.03964.x","volume":"72","author":"Z Xu","year":"2011","unstructured":"Xu Z, Bouman-Thio E, Comisar C, et al. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br J Clin Pharmacol. 2011;72(2):270\u201381.","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"455_CR34","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1136\/annrheumdis-2013-205137","volume":"73","author":"JS Smolen","year":"2014","unstructured":"Smolen JS, Weinblatt ME, Sheng S, Zhuang Y, Hsu B. Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2014;73(9):1616\u201325.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"455_CR35","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1002\/art.38091","volume":"65","author":"JC Szepietowski","year":"2013","unstructured":"Szepietowski JC, Nilganuwong S, Wozniacka A, et al. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis Rheum. 2013;65(10):2661\u201371.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"455_CR36","doi-asserted-by":"crossref","first-page":"187","DOI":"10.5414\/CP201785","volume":"51","author":"Y Zhuang","year":"2013","unstructured":"Zhuang Y, Xu Z, de Vries DE, et al. Pharmacokinetics and safety of sirukumab following a single subcutaneous administration to healthy Japanese and Caucasian subjects. Int J Clin Pharmacol Ther. 2013;51(3):187\u201399.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"3","key":"455_CR37","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.nbd.2006.05.001","volume":"23","author":"S Chourbaji","year":"2006","unstructured":"Chourbaji S, Urani A, Inta I, et al. IL-6 knockout mice exhibit resistance to stress-induced development of depression-like behaviors. Neurobiol Dis. 2006;23(3):587\u201394.","journal-title":"Neurobiol Dis"},{"key":"455_CR38","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1038\/tp.2012.120","volume":"2","author":"SJ Sukoff Rizzo","year":"2012","unstructured":"Sukoff Rizzo SJ, Neal SJ, Hughes ZA, et al. Evidence for sustained elevation of IL-6 in the CNS as a key contributor of depressive-like phenotypes. Transl Psychiatry. 2012;2:e199.","journal-title":"Transl Psychiatry"},{"issue":"45","key":"455_CR39","doi-asserted-by":"crossref","first-page":"16136","DOI":"10.1073\/pnas.1415191111","volume":"111","author":"GE Hodes","year":"2014","unstructured":"Hodes GE, Pfau ML, Leboeuf M, et al. Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress. Proc Natl Acad Sci USA. 2014;111(45):16136\u201341.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"455_CR40","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1517\/14728222.2014.888417","volume":"18","author":"M Maes","year":"2014","unstructured":"Maes M, Anderson G, Kubera M, Berk M. Targeting classical IL-6 signalling or IL-6 trans-signalling in depression? Expert Opin Ther Targets. 2014;18(5):495\u2013512.","journal-title":"Expert Opin Ther Targets"},{"issue":"12","key":"455_CR41","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1176\/appi.ajp.2014.14010094","volume":"171","author":"R Uher","year":"2014","unstructured":"Uher R, Tansey KE, Dew T, et al. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am J Psychiatry. 2014;171(12):1278\u201386.","journal-title":"Am J Psychiatry"},{"issue":"6","key":"455_CR42","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1001\/jamapsychiatry.2014.112","volume":"71","author":"M Huhn","year":"2014","unstructured":"Huhn M, Tardy M, Spineli LM, et al. Efficacy of pharmacotherapy and psychotherapy for adult psychiatric disorders: a systematic overview of meta-analyses. JAMA Psychiatry. 2014;71(6):706\u201315.","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"455_CR43","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/2013.jamapsychiatry.4","volume":"70","author":"CL Raison","year":"2013","unstructured":"Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70(1):31\u201341.","journal-title":"JAMA Psychiatry"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-016-0455-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T23:29:23Z","timestamp":1718926163000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-016-0455-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,2]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["455"],"URL":"https:\/\/doi.org\/10.1007\/s12325-016-0455-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,2]]}}}